Company Profile
Prime Medicine Stock Price, News & Analysis
- Ticker:
- PRME
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.26 USD (+3.49%)
Close
Last updated: August 11, 2026
580M USD
Market cap
Why the stock is moving
As of Aug 11, 2026, PRME closed up 3.49% at $3.26. No new same-company headline was identified in the current news window.
Company overview
Prime Editing
Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo.
PM577
PM577 is an in vivo Prime Editing candidate designed to correct disease-causing mutations in the liver for Wilson disease.
PM647
PM647 is an in vivo liver-directed program for alpha-1 antitrypsin deficiency and is approaching clinical development on a timeline similar to PM577.
Chronic Granulomatous Disease
PM359 is an ex vivo edited cell therapy for chronic granulomatous disease. Prime Medicine is continuing regulatory dialogue with the FDA regarding a potential BLA path.
Future catalysts
- IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026.
- IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026.
- Initial clinical data from PM577 and PM647 in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Prime Medicine (PRME)?
Prime Medicine (PRME) most recently closed at 3.26 USD, a +3.49% move versus the previous session.
What is the market cap of Prime Medicine (PRME)?
Prime Medicine currently has a market capitalization of 580M USD on BioPharmSignal.
What does Prime Medicine do?
Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to correct disease-causing...
On which exchange is PRME stock listed?
Prime Medicine (PRME) is associated with NASDAQ, United States, Biopharma.
What is Prime?
Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks.
Which conditions is Prime Medicine targeting with Prime?
Prime Medicine is associated with genetic disease based on its company overview and current catalyst commentary.
How does Prime Medicine describe recent progress with Prime?
IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026. IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026. Initial clinical data from PM577 and PM647 in 2027.
What is Editing?
Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks.